Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 4/20 | 0.44 |
| ▸ | NAA50 | Q9GZZ1 | 1/20 | 0.43 |
| ▸ | CALCRL | Q16602 | 3/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.39 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.39 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30449622 | 0.91 | KEAP1 (0.48) | CAPN1CALCRLSLC6A2STAT3KEAP1 | |
| SCHEMBL30335608 | 0.88 | KEAP1 (0.49) | CAPN1CALCRLSLC6A2STAT3KEAP1 | |
| SCHEMBL26186023 | 0.88 | KEAP1 (0.49) | CAPN1CALCRLSLC6A2STAT3KEAP1 | |
| SCHEMBL26186082 | 0.88 | KEAP1 (0.49) | CAPN1CALCRLSLC6A2STAT3KEAP1 | |
| SCHEMBL29531264 | 0.86 | RAMP3 (0.48) | CAPN1KEAP1 | |
| SCHEMBL29569659 | 0.86 | CAPN1 (0.51) | CAPN1NAA50CTSBNTSR1 | |
| SCHEMBL30799477 | 0.85 | CALCRL (0.48) | CAPN1CALCRLSLC6A2CTSB | |
| SCHEMBL30059762 | 0.83 | SLC6A2 (0.50) | CAPN1NAA50CALCRLSLC6A2CTSB | |
| SCHEMBL30051457 | 0.83 | DPP4 (0.46) | CAPN1NTSR2NTSR1SORT1 | |
| SCHEMBL30240004 | 0.82 | DPP4 (0.47) | CAPN1CTSBNTSR2NTSR1SORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250018014-A1 | METHOD FOR TREATING AND/OR PREVENTING REGNASE-1-RELATED DISEASE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-01-16 | — | — | US | disclosed |
| US-20220125891-A1 | METHOD FOR TREATING AND/OR PREVENTING REGNASE-1-RELATED DISEASE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250018014-A1 | METHOD FOR TREATING AND/OR PREVENTING REGNASE-1-RELATED DISEASE | RNASE1, IRAK1, SERBP1 | CAPN1 261/4885NAA50 2067/4885CALCRL 3303/4885 |
| US-20220125891-A1 | METHOD FOR TREATING AND/OR PREVENTING REGNASE-1-RELATED DISEASE | RNASE1, IRAK1, SERBP1 | CAPN1 261/4885NAA50 2067/4885CALCRL 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.